ClinicalTrials.gg

Program

NPT 2042

A development code. Also written as “NPT 2042 (Test formula/Formulation 2)” and “NPT 2042 (Reference formula/Formulation 1)”.

Its studies are mostly in Epilepsy, Absence · Drug Resistant Epilepsy · Epilepsy, led by NeuroPro Therapeutics.

Furthest: phase 2, since Dec 23, 20243 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
NeuroPro Therapeutics30 open or runningphase 2since Dec 23, 2024Jul 15, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 15, 2024First study: phase 1 study in Epilepsy, ReflexFirst studyNCT06525649 · 5 enrolled · United States
  2. Dec 23, 2024Phase 2 study in Epilepsy, GeneralizedNCT06769659 · 14 enrolled · United States
  3. Oct 13, 2025Phase 1 study in EpilepsyNCT07222878 · 8 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07222878Epilepsy · United States1CompletedNov 4, 20258
NCT06769659Epilepsy, Generalized · United States2CompletedAug 17, 202614
NCT06525649Epilepsy, Reflex · United States1CompletedJun 26, 20255

How it is read

Names in the registry

  • “NPT 2042”, 2 entries
  • “NPT 2042 (Test formula/Formulation 2)”, 2 entries
  • “NPT 2042 (Reference formula/Formulation 1)”, 1 entry

Codes read as this program: NPT2042.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.